Organovo Holdings, Inc., a leading biotechnology company specializing in 3D bioprinting, has announced the successful pricing of its public offering. The offering consists of 6,562,500 shares of common stock and an equal number of common warrants, allowing investors to purchase up to an aggregate of 6,562,500 additional shares. The combined public offering price for each share of common stock and accompanying common warrant has been set at $0.80.
This strategic move enables Organovo to raise approximately $5.25 million in gross proceeds, which will be utilized to further advance the company’s groundbreaking research and development initiatives in the field of regenerative medicine. With its innovative 3D bioprinting technology, Organovo aims to revolutionize the way diseases are treated by creating functional human tissues for drug discovery, toxicology testing, and ultimately, therapeutic applications.